-
CUL3-Mediated BECN1 Degradation Suppresses Autophagy and Fue
2026-04-30
This study uncovers a mechanism by which the E3 ubiquitin ligase CUL3, via its adaptor KLHL38, destabilizes BECN1, leading to reduced autophagic activity and accelerated tumor progression in breast and ovarian cancers. The findings clarify how post-translational regulation of BECN1 impairs cellular homeostasis, offering new angles for therapeutic intervention targeting the ubiquitin-proteasome system.
-
Olsalazine Sodium: Mesalamine Dimer for Inflammation and Can
2026-04-30
Olsalazine Sodium, a mesalamine dimer, is a potent inhibitor of LTB4-induced chemotaxis and widely used in inflammation and colorectal cancer research. Its anti-proliferative and pro-apoptotic effects are well-documented in preclinical models, with stability and workflow guidance provided by APExBIO.
-
Rottlerin: Redefining PKCδ Inhibition for Translational Rese
2026-04-29
This thought-leadership article explores the mechanistic and strategic applications of Rottlerin, a selective PKCδ inhibitor, in translational research. Integrating landmark studies on cell proliferation, apoptosis, and pathogen-host interactions, it provides actionable insights for researchers navigating the complexities of PKC signaling pathways. The article uniquely synthesizes cross-domain evidence, highlights protocol parameters, and sets a visionary agenda for next-generation experimental design using Rottlerin from APExBIO.
-
Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237
2026-04-29
The Hoechst 33342/PI Double Staining Kit offers a practical, fluorescence-based method for distinguishing viable, apoptotic, and necrotic cells by assessing nuclear chromatin condensation and membrane integrity. It is designed for basic research workflows involving cell death analysis, not for diagnostic or clinical applications.
-
Patient-Derived Gastric Cancer Assembloid Models Advance Dru
2026-04-28
This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, closely recapitulating tumor microenvironment complexity. The model enables more physiologically relevant drug response profiling, supporting personalized therapy and resistance mechanism discovery.
-
ATM Inhibition Induces Macropinocytosis and Reveals Tumor Vu
2026-04-28
This study reveals that ATM kinase inhibition drives cancer cell metabolic adaptation by inducing macropinocytosis, enabling survival under nutrient-limited conditions. These findings highlight a novel vulnerability in tumor metabolism that is exploitable for therapeutic research.
-
Chicken GSDME as a Key Effector in RNA Virus-Induced Pyropto
2026-04-27
Chen et al. demonstrate that chicken GSDME, not GSDMD, drives pyroptosis in response to RNA virus infection via MDA5-caspase-3/7 signaling. This finding clarifies avian pyroptotic mechanisms and offers new directions for immune cell death research in veterinary virology.
-
Viral-Mediated RIPK3 Degradation Modulates Necroptosis and I
2026-04-27
Liu et al. identify a class of orthopoxvirus proteins, termed vIRD, that target and degrade RIPK3 to suppress necroptosis and modulate virus-induced inflammation. These findings clarify a key viral strategy in evading host cell death pathways and have direct implications for research on regulated cell death and inflammation in infectious disease models.
-
Dissecting Drug Response Metrics in Cancer: Insights from In
2026-04-26
Schwartz’s doctoral research advances the evaluation of anti-cancer drugs by distinguishing between proliferative arrest and cell death in in vitro models. By clarifying how relative and fractional viability metrics diverge, the study provides a nuanced framework for interpreting responses to agents like survivin inhibitors and offers guidance for translational oncology assay design.
-
SP1/ADAM10/DRP1 Axis Orchestrates EC–SMC Crosstalk in Hypoxi
2026-04-25
This study reveals that the SP1/ADAM10/DRP1 signaling axis mediates intercellular communication between endothelial and smooth muscle cells under hypoxic pulmonary hypertension. By elucidating how ADAM10 secretion from hypoxia-exposed endothelial cells drives pathological proliferation and apoptosis resistance in smooth muscle cells via DRP1 and PI3K/AKT/mTOR pathways, the work uncovers new therapeutic targets for pulmonary vascular remodeling.
-
Procainamide Hydrochloride: Applied Workflows in Cardiac and
2026-04-24
Procainamide Hydrochloride unlocks advanced cardiac and oncology research through its dual role as a sodium channel blocker and DNMT1 inhibitor. This guide details experimental setups, liposomal delivery innovations, and troubleshooting for maximized assay performance.
-
Bestatin (Ubenimex): Reliable Aminopeptidase Inhibition in C
2026-04-24
This article delivers practical, scenario-driven guidance for deploying Bestatin (Ubenimex) (SKU A2575) in sensitive cell-based assays. Drawing on quantitative literature and validated workflows, it outlines how this aminopeptidase inhibitor from APExBIO enables reproducible results for apoptosis, multidrug resistance, and cancer research.
-
20-HETE, TRPV1, and MrgprA3+ Neurons: Mechanisms of Chronic
2026-04-23
This study elucidates how the arachidonic acid metabolite 20-HETE mediates activation of TRPV1 channels on MrgprA3+ sensory neurons, inducing allokinesis and chronic itch in dermatitis. The findings clarify peripheral mechanisms of itch/pain crossover and highlight new intervention strategies targeting TRPV1-MrgprA3+ pathways in chronic skin inflammation.
-
Aneugenicity Mechanisms: Insights from Tiered Molecular Assa
2026-04-23
This study introduces a robust tiered assay framework to elucidate the molecular mechanisms underlying chemical-induced aneugenicity, distinguishing tubulin binders from mitotic kinase inhibitors with high accuracy. The findings have significant implications for mechanistic toxicology, chemical risk assessment, and the validation of microtubule-associated inhibitors in research workflows.
-
CA-074 Me (Cathepsin B inhibitor): Reliable Lysosomal Enzyme
2026-04-22
This article addresses common challenges in cell viability and apoptosis assays, highlighting how CA-074 Me (Cathepsin B inhibitor, SKU A8239) from APExBIO offers robust, data-backed solutions for lysosomal enzyme inhibition. Evidence-based scenarios clarify protocol optimization, experimental design, and vendor selection to ensure reproducibility and sensitivity in cathepsin B-related research.